Biomedicines

Journal Browser

► Journal Browser

Pathogenesis, Diagnosis, and Treatment of Respiratory Diseases

Share This Special Issue

Special Issue Editor

Special Issue Information

Dear Colleagues,

COVID-19 has had a huge impact on our lives. Thus, we must pay more attention to respiratory diseases, particularly their molecular mechanisms, diagnosis, and treatment. These actions will directly affect and contribute to the survival of human beings.

This Special Issue aims to collect various research articles on respiratory diseases. Studies focusing on the molecular mechanisms, pathogenesis, diagnosis, treatment, and prognosis of these diseases will be prioritized. This Special Issue will improve our understanding of the occurrence of respiratory diseases and possible approaches to early diagnosis and precise treatment.

In this Special Issue, original clinical and basic research articles and reviews are welcome. Research areas may include (but are not limited to) the following: COPD, asthma, interstitial lung disease, lung cancer, pneumonia, tuberculosis, respiratory failure, ARDS, COVID-19, and obstructive sleep apnea. I look forward to receiving your contributions.

Dr. Te-Chun Shen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.

Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.

Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.

External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.

e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

15 pages, 5770 KiB

Open AccessArticle

PGC1-Alpha/Sirt3 Signaling Pathway Mediates the Anti-Pulmonary Fibrosis Effect of Hirudin by Inhibiting Fibroblast Senescence

by Bin He, Qian Zeng, Yumei Tian, Yuyang Luo, Minlin Liao, Wenjie Huang, Bin Wu, Ziqiang Luo, Xiaoting Huang, Wei Liu and Siyuan Tang

Biomedicines 2024, 12(7), 1436; https://doi.org/10.3390/biomedicines12071436 - 27 Jun 2024

Cited by 1 | Viewed by 1538

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrotic lung disease for which there is a lack of effective pharmacological treatments. Hirudin, a natural peptide extracted from leeches, has been used for broad pharmacological purposes. In this study, we investigated the therapeutic effects of hirudin on IPF and its related mechanism of action. By constructing a mouse model of pulmonary fibrosis and treating it with hirudin in vivo, we found that hirudin exerted anti-fibrotic, anti-oxidative, and anti-fibroblast senescence effects. Moreover, using an in vitro model of stress-induced premature senescence in primary mouse lung fibroblasts and treating with hirudin, we observed inhibition of fibroblast senescence and upregulation of PGC1-alpha and Sirt3 expression. However, specific silencing of PGC1-alpha or Sirt3 suppressed the anti-fibroblast senescence effect of hirudin. Thus, the PGC1-alpha/Sirt3 pathway mediates the anti-fibroblast senescence effect of hirudin, potentially serving as a molecular mechanism underlying its anti-fibrosis and anti-oxidative stress effects exerted on the lungs. Full article

(This article belongs to the Special Issue Pathogenesis, Diagnosis, and Treatment of Respiratory Diseases)

► Show Figures

Figure 1

Figure 1
Hirudin has a therapeutic effect in bleomycin-induced lung fibrosis in mice. Bleomycin tracheal injection was used to create a pulmonary fibrosis model. From days 15 to 28, intraperitoneal injections of hirudin at high, moderate, and low doses were then administered. Histopathological structure and ECM deposition changes in mouse lung tissue (A,B). The overall fibrosis of lung tissue in groups of mice (C). The level of hydroxyproline in mouse lung tissue (D). The mRNA expression levels of Col1a1 and ACTA2 (E,F). The amount of type I collagen and α-SMA in mouse lung tissues (G). BLM + H, 10 mg/kg group; BLM + M, 3 mg/kg group; BLM + L, 1 mg/kg group; BLM, pulmonary fibrosis model group; and Control, control group. All data are expressed in the mean ± standard deviation; n = 8, * p < 0.05; ** p < 0.01; *** p < 0.001; and **** p < 0.0001. Full article ">Figure 2
Hirudin inhibits oxidative stress in bleomycin-induced lung fibrosis. The levels of ROS in lung tissues (A).The MDA levels, GSH levels, and total SOD levels in lung tissues (B–D). BLM + H, 10 mg/kg group; BLM + M, 3 mg/kg group; BLM + L, 1 mg/kg group; BLM, pulmonary fibrosis model group; and Control, control group. All data are expressed in the mean ± standard deviation; n = 8; ** p < 0.01; and **** p < 0.0001. Full article ">Figure 3
Hirudin inhibits fibroblast senescence in bleomycin-induced lung fibrosis. The levels of fibrosis and fibroblast senescence in mouse lung tissues (A). The mRNA expression levels of IL1b, IL6, IL8, and TNF-α in mouse lung tissues (B–E). The protein expression levels of p21, p16, PGC1-alpha, and Sirt3 in mouse lung tissues (F,I). The mRNA expression levels of p21 and p16 in mouse lung tissues (G,H). The mRNA expression levels of PGC1-alpha and Sirt3 in mouse lung tissues (J,K). BLM + H, 10 mg/kg group; BLM + M, 3 mg/kg group; BLM + L, 1 mg/kg group; BLM, pulmonary fibrosis model group; and Control, control group. All data are expressed in the mean ± standard deviation; n = 8; **** p < 0.0001; *** p < 0.001; ** p < 0.01; and * p < 0.05. Full article ">Figure 4
Hirudin has an inhibitory effect on hydrogen peroxide-induced senescence in fibroblasts. The effect of hirudin on the viability of fibroblasts (A). The level of ROS in fibroblasts (B). The β-galactosidase levels in fibroblasts (C). The mRNA expression levels of IL1b, IL6, IL8, and TNF-α in fibroblasts (D–G). The mRNA expression levels of p21 and p16 in fibroblasts (I,J). The expression of p21 in fibroblasts (H). The protein expression levels of p21 and p16 in fibroblasts (K). All data are presented as mean ± standard deviation, and all experiments were conducted independently and repeated a minimum of three times. * p < 0.05; ** p < 0.01; *** p < 0.001; and **** p < 0.0001. Full article ">Figure 5
Hirudin activated the PGC1-alpha/Sirt3 pathway to inhibit fibroblast senescence. The protein expression levels of PGC1-alpha and Sirt3 in fibroblasts (A). The mRNA expression levels of PGC1-alpha and Sirt3 in fibroblasts (B,C). The levels of ROS in fibroblasts (D). β-galactosidase levels in fibroblasts (E). The mRNA expression levels of IL1b, TNF-α, IL8, and IL6 in fibroblasts (F–I). The expression of p21 in fibroblasts (J). The protein expression levels of p21 and p16 in fibroblasts (K). The mRNA expression levels of p21 and p16 in fibroblasts (L,M). All data are expressed in the mean ± standard deviation, and all experiments were conducted independently and repeated a minimum of three times. ** p < 0.01; **** p < 0.0001. Full article ">Figure 6
Schematic of a model of the anti-pulmonary fibrosis effect of hirudin. Full article ">

Journal Menu

Journal Browser

Pathogenesis, Diagnosis, and Treatment of Respiratory Diseases

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Benefits of Publishing in a Special Issue

Published Papers (1 paper)

Research

Further Information

Guidelines

MDPI Initiatives

Follow MDPI